Researchers successfully designed CD40L-carrying exosomes that possess a stronger ability to trigger maturation of DCs by integrating the features of tumor antigens in TEX, CD40/CD40L targeting DCs, and CD40 signaling (49). The gene discussed is CD40; the disease is neoplasm.